Clinical

Dataset Information

0

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer


ABSTRACT: This is an open label, randomized, phase Ⅲ study to treat subjects with RAS/BRAF wild-type, unresectable metastatic colorectal cancer. The patients will be randomized into two arms consist of Anlotinib (3 weeks/cycle) + CapeOx and Bevacizumab (3 week/cycle) + CapeOx at a ratio of 1:1. This study is conducted to assess the efficacy and safety of Anlotinib and Chemotherapy as first-line treatment in subjects with RAS/BRAF wild-type Metastatic Colorectal Cancer.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2375058 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2315608 | ecrin-mdr-crc
2019-07-01 | E-MTAB-7068 | biostudies-arrayexpress
2020-11-09 | GSE142031 | GEO
2021-05-01 | GSE149901 | GEO
| 2391480 | ecrin-mdr-crc
2019-01-01 | GSE109468 | GEO
2020-12-21 | GSE163574 | GEO
| PRJEB27916 | ENA
2018-11-30 | E-MTAB-5997 | biostudies-arrayexpress
2024-07-31 | GSE237818 | GEO